CJC-1295 vs Tesamorelin
Head-to-head comparison of CJC-1295 and Tesamorelin for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Tesamorelin |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of... |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Not approved for human use | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Common: injection site reactions (17%), arthralgia (13%), myalgia (6%), peripheral edema (6%); Headache, nausea, and flu-like symptoms reported |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 2 mg/day SC (FDA-approved dose) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~5135.9 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~26–38 minutes |
Overview
CJC-1295 and Tesamorelin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
Tesamorelin 10mg
10mg
CJC-1295 DAC 5mg
5mg
Tesamorelin — Mechanism & Evidence
Tesamorelin (tesamorelin acetate) is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH) and the only FDA-approved medication for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, marketed as Egrifta. It stimulates endogenous GH and IGF-1 production. Egrifta WR, a new weekly-reconstitution formulation, was FDA-approved in March 2025. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.
Key claims: Reduces visceral adipose tissue in HIV lipodystrophy; Increases skeletal muscle area and density; Effective on INSTI-based HIV regimens.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
Tesamorelin is also researched for: no additional unique applications.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Tesamorelin: Common: injection site reactions (17%), arthralgia (13%), myalgia (6%), peripheral edema (6%) Headache, nausea, and flu-like symptoms reported May increase blood glucose -- monitoring recommended in diabetics
Shop Research Peptides
Tesamorelin 10mg
10mg
CJC-1295 DAC 5mg
5mg
Retatrutide 20mg
20mg
BPC-157 5mg
5mg
Ipamorelin 10mg
10mg
Semaglutide 10mg
10mg
TB-500 5mg
5mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Tesamorelin Research Interest Grows Among Synthetic GHRPs
Synthetic growth hormone-releasing peptides (GHRPs) are drawing increasing attention in scientific research, with tesamorelin emerging as a focal point. The compound, a synthetic analog of growth hormone-releasing hormone, is being studied for its potential to modulate growth hormone levels. This article examines the rising research interest in tesamorelin and its place within the broader class of synthetic GHRPs.
Tesamorelin Manufacturing News: Peptide CDMO Market to Reach $11.42B by 2035
The peptide and oligonucleotide CDMO market is projected to reach USD 11.42 billion by 2035, driven by regulatory shifts and increased demand for research compounds. Recent FDA panel recommendations to ease restrictions on peptides like BPC-157 and tesamorelin signal potential manufacturing expansion. This analysis explores capacity changes and industry implications.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe